JP2008540507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540507A5 JP2008540507A5 JP2008510671A JP2008510671A JP2008540507A5 JP 2008540507 A5 JP2008540507 A5 JP 2008540507A5 JP 2008510671 A JP2008510671 A JP 2008510671A JP 2008510671 A JP2008510671 A JP 2008510671A JP 2008540507 A5 JP2008540507 A5 JP 2008540507A5
- Authority
- JP
- Japan
- Prior art keywords
- active substance
- antibiotic
- therapeutically active
- ionone
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 20
- 239000013543 active substance Substances 0.000 claims 17
- 230000003115 biocidal effect Effects 0.000 claims 14
- 229960003022 amoxicillin Drugs 0.000 claims 10
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims 10
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims 10
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims 10
- PSQYTAPXSHCGMF-BQYQJAHWSA-N β-ionone Chemical compound CC(=O)\C=C\C1=C(C)CCCC1(C)C PSQYTAPXSHCGMF-BQYQJAHWSA-N 0.000 claims 10
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 8
- 239000004098 Tetracycline Substances 0.000 claims 6
- 239000005844 Thymol Substances 0.000 claims 6
- UZFLPKAIBPNNCA-UHFFFAOYSA-N alpha-ionone Natural products CC(=O)C=CC1C(C)=CCCC1(C)C UZFLPKAIBPNNCA-UHFFFAOYSA-N 0.000 claims 6
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims 6
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims 6
- 235000007746 carvacrol Nutrition 0.000 claims 6
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims 6
- 235000019364 tetracycline Nutrition 0.000 claims 6
- 150000003522 tetracyclines Chemical class 0.000 claims 6
- 229960000790 thymol Drugs 0.000 claims 6
- SFEOKXHPFMOVRM-UHFFFAOYSA-N (+)-(S)-gamma-ionone Natural products CC(=O)C=CC1C(=C)CCCC1(C)C SFEOKXHPFMOVRM-UHFFFAOYSA-N 0.000 claims 5
- BAVONGHXFVOKBV-UHFFFAOYSA-N Carveol Chemical compound CC(=C)C1CC=C(C)C(O)C1 BAVONGHXFVOKBV-UHFFFAOYSA-N 0.000 claims 4
- 239000004099 Chlortetracycline Substances 0.000 claims 4
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims 4
- 108010093965 Polymyxin B Proteins 0.000 claims 4
- 229960000723 ampicillin Drugs 0.000 claims 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 4
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims 4
- 229960001139 cefazolin Drugs 0.000 claims 4
- 229960005091 chloramphenicol Drugs 0.000 claims 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims 4
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims 4
- 229960004475 chlortetracycline Drugs 0.000 claims 4
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims 4
- 235000019365 chlortetracycline Nutrition 0.000 claims 4
- 229960003324 clavulanic acid Drugs 0.000 claims 4
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims 4
- 229960003276 erythromycin Drugs 0.000 claims 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims 4
- 229960003350 isoniazid Drugs 0.000 claims 4
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 4
- 229920000024 polymyxin B Polymers 0.000 claims 4
- 229960005266 polymyxin b Drugs 0.000 claims 4
- 229960001225 rifampicin Drugs 0.000 claims 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 4
- 229960005322 streptomycin Drugs 0.000 claims 4
- 229960002180 tetracycline Drugs 0.000 claims 4
- 229930101283 tetracycline Natural products 0.000 claims 4
- UZFLPKAIBPNNCA-FPLPWBNLSA-N α-ionone Chemical compound CC(=O)\C=C/C1C(C)=CCCC1(C)C UZFLPKAIBPNNCA-FPLPWBNLSA-N 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims 2
- BAVONGHXFVOKBV-ZJUUUORDSA-N (-)-trans-carveol Natural products CC(=C)[C@@H]1CC=C(C)[C@@H](O)C1 BAVONGHXFVOKBV-ZJUUUORDSA-N 0.000 claims 2
- 229930186147 Cephalosporin Natural products 0.000 claims 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims 2
- 239000005770 Eugenol Substances 0.000 claims 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims 2
- 229930189077 Rifamycin Natural products 0.000 claims 2
- 125000001597 alpha-ionone group Chemical group 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 229940116229 borneol Drugs 0.000 claims 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims 2
- 229930007646 carveol Natural products 0.000 claims 2
- 229940124587 cephalosporin Drugs 0.000 claims 2
- 150000001780 cephalosporins Chemical class 0.000 claims 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims 2
- 229960002217 eugenol Drugs 0.000 claims 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 2
- 229940041033 macrolides Drugs 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 claims 2
- 229940081192 rifamycins Drugs 0.000 claims 2
- 229940040944 tetracyclines Drugs 0.000 claims 2
- 125000003639 thymyl group Chemical group C1(=CC(C)=CC=C1C(C)C)* 0.000 claims 2
- 150000003952 β-lactams Chemical class 0.000 claims 2
- 229920001817 Agar Polymers 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229930002839 ionone Natural products 0.000 claims 1
- 150000002499 ionone derivatives Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2005/001313 WO2006120494A1 (fr) | 2005-05-13 | 2005-05-13 | Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l’eugenol, le borneol et les carvacrol |
| IBPCT/IB2005/001313 | 2005-05-13 | ||
| PCT/IB2006/001350 WO2006120567A2 (fr) | 2005-05-13 | 2006-05-15 | Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008540507A JP2008540507A (ja) | 2008-11-20 |
| JP2008540507A5 true JP2008540507A5 (https=) | 2009-07-02 |
| JP5410748B2 JP5410748B2 (ja) | 2014-02-05 |
Family
ID=35427275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510671A Active JP5410748B2 (ja) | 2005-05-13 | 2006-05-15 | 抗菌剤およびカルベオール、チモール、オイゲノール、ボルネオールならびにカルバクロールから選択される活性成分を含んでなる医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080214518A1 (https=) |
| EP (1) | EP1879655B1 (https=) |
| JP (1) | JP5410748B2 (https=) |
| CN (3) | CN102319246B (https=) |
| BR (1) | BRPI0610125B8 (https=) |
| CA (1) | CA2606875C (https=) |
| DK (1) | DK1879655T3 (https=) |
| EA (1) | EA014069B1 (https=) |
| ES (1) | ES2530963T3 (https=) |
| MA (1) | MA29606B1 (https=) |
| PT (1) | PT1879655E (https=) |
| TN (1) | TNSN07424A1 (https=) |
| WO (2) | WO2006120494A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2918571B1 (fr) * | 2007-07-10 | 2013-01-11 | Aroma Tech | Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales |
| EP2214656B1 (en) * | 2007-10-26 | 2018-12-05 | Avivagen Inc. | Compositions and methods for enhancing immune response |
| FR2925334A1 (fr) * | 2007-12-21 | 2009-06-26 | Ceva Sante Animale Sa | Nouvelles compositions antibacteriennes |
| AU2010242502B2 (en) | 2009-04-30 | 2016-11-10 | Avivagen Inc. | Methods and compositions for improving the health of animals |
| AU2010297406B2 (en) | 2009-09-24 | 2013-10-17 | Unilever Plc | Disinfecting agent comprising eugenol, terpineol and thymol |
| WO2012076310A1 (en) | 2010-12-07 | 2012-06-14 | Unilever Nv | An oral care composition |
| MX2014005405A (es) | 2011-11-03 | 2014-06-23 | Unilever Nv | Una composicion de limpieza personal. |
| MX347858B (es) | 2011-12-06 | 2017-05-16 | Unilever Nv | Composición antimicrobiana. |
| CN102670619B (zh) * | 2012-05-08 | 2014-02-19 | 广东药学院 | 一种头孢氨苄冰片组合物 |
| CN102670598B (zh) * | 2012-05-08 | 2014-07-16 | 广东药学院 | 一种青霉素冰片组合物在制备抗菌药物中的应用 |
| CN103146255B (zh) * | 2013-02-25 | 2014-07-09 | 厦门吉宏包装科技有限公司 | 一种抑菌驱螨印刷底油母液和由母液制作的印刷底油及其制备方法 |
| CN105357971A (zh) * | 2013-05-07 | 2016-02-24 | 凯敏工业公司 | 含有香芹酚和麝香草酚的抗微生物组合物 |
| FR3025719A1 (fr) | 2014-09-15 | 2016-03-18 | Septeos | Antimicrobiens potentialises |
| FR3025718A1 (fr) | 2014-09-15 | 2016-03-18 | Septeos | Antimicrobiens potentialises |
| WO2016081594A1 (en) * | 2014-11-19 | 2016-05-26 | The General Hospital Corporation | System and method for photo-dynamic procedure |
| HK1243951A1 (zh) * | 2014-12-18 | 2018-07-27 | Helperby Therapeutics Limited | 抗微生物组合和其在治疗微生物感染中的用途 |
| CN107530397A (zh) * | 2014-12-18 | 2018-01-02 | 赫尔普百治疗有限公司 | 新型组合和用途 |
| CN109512998A (zh) * | 2016-03-04 | 2019-03-26 | 广州英赛特生物技术有限公司 | 含氧碳氢衍生物的酯化衍生物作为多粘菌素的协同增效剂的应用 |
| FR3048612B1 (fr) * | 2016-03-14 | 2020-10-02 | Septeos | Tulathromycine potentialisee |
| WO2017209588A2 (fr) | 2016-06-02 | 2017-12-07 | Advanced Scientific Developements | Formulation pharmaceutique de cinéol et d'amoxicilline |
| GB201904963D0 (en) * | 2019-04-08 | 2019-05-22 | Anpario Plc | Composition for reducing antimicrobial resistance |
| ES2986948T3 (es) | 2019-12-04 | 2024-11-13 | Pranarom Int S A | Procedimiento de transformación de un aceite esencial |
| KR102848354B1 (ko) * | 2023-02-13 | 2025-08-21 | 경상국립대학교산학협력단 | 테트라사이클린계 항생제와 시너지 효과를 가지는 바닐린 또는 카바크롤을 유효성분으로 포함하는 조성물 및 이의 용도 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4317775A (en) * | 1980-01-07 | 1982-03-02 | Hoffmann-La Roche Inc. | Amoxicillin derivatives |
| DE3634697A1 (de) * | 1986-10-11 | 1988-04-21 | Dentaire Ivoclar Ets | Dentalwerkstoff zur bekaempfung von karies und parodontose |
| US5213615A (en) * | 1986-10-11 | 1993-05-25 | Ivoclar Ag | Dental material and method for the control of caries and paradentitis |
| US5801153A (en) * | 1991-09-13 | 1998-09-01 | Badaway; Mohammed A. | Method of enhancing the antimicrobial properties of antibacterial antibiotics to massively control and prevent bacterial, fungal, and viral diseases in plants |
| FR2697133B1 (fr) * | 1992-10-28 | 1995-01-13 | Transbiotech | Composition biocide et/ou biostatique et ses applications. |
| US5308873A (en) * | 1992-12-18 | 1994-05-03 | Doyle E. Chastain | Method of killing yeast and fungi with carveol |
| US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| CA2224227A1 (en) * | 1995-06-07 | 1996-12-19 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US6319507B1 (en) * | 1997-05-02 | 2001-11-20 | Kobo Products, Inc. | Agar gel bead composition and method |
| US6025400A (en) * | 1998-08-24 | 2000-02-15 | Marco Polo Technologies | Compositions for treatment of antibiotic-resistant gram-positive bacterial infections and methods for using and preparing the same |
| SE9901733L (sv) * | 1999-05-12 | 2000-11-13 | Akzo Nobel Nv | En komposition innehållande karvakrol och tymol för användning som bactericid |
| US6414036B1 (en) * | 1999-09-01 | 2002-07-02 | Van Beek Global/Ninkov Llc | Composition for treatment of infections of humans and animals |
| US6495512B1 (en) * | 2000-06-23 | 2002-12-17 | International Flavors & Fragrances Inc. | Salicylaldehyde-containing composition having antimicrobial and fragrancing properties and process for using same |
| AU2002211536A1 (en) * | 2000-10-06 | 2002-04-15 | Dusan Ninkov | Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals |
| US6787568B1 (en) * | 2000-11-27 | 2004-09-07 | Phoenix Scientific, Inc. | Antibiotic/analgesic formulation and a method of making this formulation |
| US20030064948A1 (en) * | 2001-02-08 | 2003-04-03 | Alfred Fahr | Invasomes for therapy of disorders, their preparation and use |
| US6585963B1 (en) * | 2001-02-15 | 2003-07-01 | Watson Pharmaceuticals, Inc. | Nail compositions and methods of administering same |
| US20030180349A1 (en) * | 2001-12-07 | 2003-09-25 | Franklin Lanny U. | Respiratory infection prevention and treatment with terpene-containing compositions |
| US20030225003A1 (en) * | 2002-04-18 | 2003-12-04 | Dusan Ninkov | Antimicrobial therapeutic compositions for oral and topical use |
| WO2004045572A1 (en) * | 2002-11-21 | 2004-06-03 | J.P.M.E.D. Ltd. | Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil |
| EA200500804A1 (ru) * | 2002-12-10 | 2005-12-29 | Биосинексус Инкорпорейтед | Топические противоинфекционные композиции |
| US20040151771A1 (en) * | 2003-02-04 | 2004-08-05 | Gin Jerry B. | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth |
| EP2338332B1 (en) * | 2004-05-20 | 2014-02-12 | Eden Research Plc | Hollow glucan particle or cell wall particle encapsulating a terpene component |
-
2005
- 2005-05-13 WO PCT/IB2005/001313 patent/WO2006120494A1/fr not_active Ceased
-
2006
- 2006-05-15 CN CN2011101912078A patent/CN102319246B/zh active Active
- 2006-05-15 JP JP2008510671A patent/JP5410748B2/ja active Active
- 2006-05-15 CN CN201310230786.1A patent/CN103356612B/zh active Active
- 2006-05-15 DK DK06744753.2T patent/DK1879655T3/en active
- 2006-05-15 EA EA200702483A patent/EA014069B1/ru not_active IP Right Cessation
- 2006-05-15 WO PCT/IB2006/001350 patent/WO2006120567A2/fr not_active Ceased
- 2006-05-15 CN CN2006800164912A patent/CN101175531B/zh active Active
- 2006-05-15 CA CA2606875A patent/CA2606875C/fr active Active
- 2006-05-15 EP EP06744753.2A patent/EP1879655B1/fr active Active
- 2006-05-15 BR BRPI0610125A patent/BRPI0610125B8/pt active IP Right Grant
- 2006-05-15 ES ES06744753T patent/ES2530963T3/es active Active
- 2006-05-15 US US11/914,015 patent/US20080214518A1/en not_active Abandoned
- 2006-05-15 PT PT67447532T patent/PT1879655E/pt unknown
-
2007
- 2007-11-13 TN TNP2007000424A patent/TNSN07424A1/fr unknown
- 2007-12-28 MA MA30530A patent/MA29606B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540507A5 (https=) | ||
| RU2685730C1 (ru) | Составы соединений азаиндола | |
| ES2772754T3 (es) | Pemafibrato para uso en el tratamiento de la enfermedad del hígado graso no alcohólico | |
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| JP2005515996A5 (https=) | ||
| JP2002538110A5 (https=) | ||
| WO2010103544A3 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| JP2011173928A5 (https=) | ||
| JP2012520866A5 (https=) | ||
| EA200901277A1 (ru) | Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина | |
| JP2009102342A5 (https=) | ||
| JP2013511507A5 (https=) | ||
| KR20230027150A (ko) | 코로나바이러스 감염 치료용 화합물 | |
| JP2020514282A5 (https=) | ||
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| JP2008543936A5 (https=) | ||
| JP2013508282A5 (https=) | ||
| CN104840467A (zh) | 五环三萜类肠道病毒ev71抑制剂、其药物组合物及医药用途 | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| JP2008540506A5 (https=) | ||
| EP2540294A4 (en) | SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION | |
| NO20082181L (no) | Formuleringer av Fispemifen | |
| JP2017514858A5 (https=) | ||
| MX2011011526A (es) | Formulacion lipida de promotor de apoptosis. | |
| JP2018513193A5 (https=) |